RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...

Baron Funds, an investment management company, released its “Baron Asset Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. stocks rose amid volatility caused ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

We came across a bullish thesis on Bio-Techne Corporation on Stock Analysis Compilation’s Substack. In this article, we will summarize the bulls’ thesis on TECH. Bio-Techne Corporation’s share was ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S. equity ...

BIO-TECHNE ($TECH) posted quarterly earnings results on Wednesday, February 5th. The company reported earnings of $0.42 per share, beating estimates of $0.39 by $0.03 ...

Bio-Techne faces significant macro and policy headwinds, including reduced academic research funding, China risks, and U.S. healthcare reforms, limiting near-term growth. Despite a solid business ...

Bio-Techne develops, manufactures and sells life science reagents, instruments and services for the research, pharmaceutical, diagnostics and bioprocessing markets worldwide. In 2013, Bio-Techne ...

In trading on Monday, shares of Bio-Techne Corp (Symbol: TECH) crossed above their 200 day moving average of $73.66, changing hands as high as $74.93 per share. Bio-Techne Corp shares are currently ...

In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...